Before nanoparticles can be considered as a realistic drug delivery method, there are several properties the system needs to fulfill . These are the following:
stable in blood nontoxic nonthrombogenic nonimmunogenic noninflammatory no activation of neutrophils biodegradable avoidance of the reticuloendothelial system applicable to various molecules, such as small molecules, proteins, peptides, or nucleic acids (platform technology)
• scalable and inexpensive manufacturing process.
Because poly(butylcyanoacrylate) nanoparticles possess these properties they were reported to be useful tools for drug delivery to the brain in the several in vivo experiments. In addition, they exhibit very low (if any) toxicity and are considered to be relatively nontoxic. Their toxicity toward hepatocytes is rather low with an LD50 at about 0.4 mg/2 x 106 cells . The LD50 in mice is 230 mg/kg after intrave-neous application .
Was this article helpful?